I agree that a CR won't have much/any adverse impact on the SP....

I agree that a CR won't have much/any adverse impact on the SP. On occasion SP's have gone a up a little after a small CR to sophs as (depending on who the sophs are) if they are a fund/insto etc and have a good reputation etc it sends a signal to the retail sector that there is high-level interest and backing.

There are other ASX-listed biotech and biomedical species out there with over 1b shares on issue and are as diluted as boarding school cordial so I think TIS have done well to keep the register comparitively tight while progressing the project to approval stage.

How many shares on issue currently - 300M?